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1 Abbreviations: aSyn, alpha-synuclein; cell lines stably overexpressing human A53T mutated 
form of aSyn, [A53T]aSyn or A30P mutated form of aSyn, [A30P]aSyn; high-molecular-
weight, HMW; microtubule-associated protein light chain 3B I-II, LC3BI-II; negative control, 
NC; optical density, OD; Parkinson’s disease, PD; prolyl oligopeptidase, PREP; ubiquitin-
proteasome system, UPS; Western blot, WB; Wild type, Wt. 
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Abstract 
Lewy bodies, the histopathological hallmarks of Parkinson’s disease (PD), contain insoluble 
and aggregated α-synuclein (aSyn) and many other proteins, proposing a role for failure in 
protein degradation system in the PD pathogenesis. Proteasomal dysfunction has indeed been 
linked to PD and aSyn oligomers have been shown to inhibit proteasomes and autophagy. Our 
recent studies have shown that inhibitors of prolyl oligopeptidase (PREP) can prevent the 
aggregation and enhance the clearance of accumulated aSyn, and therefore, we wanted to study 
if PREP inhibition can overcome the aSyn aggregation and toxicity induced by lactacystin, a 
proteasomal inhibitor. The cells overexpressing human A30P or A53T mutated aSyn were 
incubated with lactacystin and a PREP inhibitor, KYP-2047, for 48 h. Theafter, the cells were 
fractioned, and the effects of lactacystin with/without 1 µM KYP-2047 on aSyn aggregation 
and ubiquitin accumulation, cell viability and on autophagic markers (p62, Beclin1 and 
LC3BII) were studied. We found that KYP-2047 attenuated lactacystin-induced cell death in 
mutant aSyn overexpressing cells but not in non-overexpressing control cells. KYP-2047 
reduced significantly SDS-insoluble high-molecular-weight aSyn oligomers that was in line 
with the cell viability results. In addition, significant reduction in protein accumulation marker, 
p62, was seen in SDS fraction while LC3BII, a marker for autophagosome formation, was 
increased, indicating to enhanced autophagy. Our results further streghten the possibilities for 
PREP inhibitors as a potential drug therapy against synucleinopathies and other protein 
aggregating diseases.  
 
Keywords: Serine protease, Parkinson’s disease, synucleinopathies, alpha-synuclein 
aggregation, enzyme inhibition 
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Introduction  
In Parkinson’s disease (PD), degeneration of dopaminergic neurons in substantia nigra and 
striatum leads to progressing movement deficits. The cause for this neurodegeneration is not 
known but histopathological findings of PD are insoluble inclusions, Lewy bodies, mainly 
consisting of an α-synuclein (aSyn) [1]. 
aSyn is a natively unfolded protein that can misfold, leading to protein aggregation, formation 
of toxic oligomers and cell-to-cell propagation of aSyn pathology [2-4]. Moreover, genome-
wide association studies have pointed aSyn gene, SNCA, as a risk factor for PD and mutations 
in SNCA are associated with familial forms of PD, supporting its participation in PD pathology 
(for review, see [5]). The most studied point mutations in SNCA are A30P and A53T, causing 
familial PD with early onset. Both of them enhance the fibrillization of aSyn, leading to aSyn 
oligomers and cellular damages, but A30P is more prone for membrane-induced aggregation 
(for review, see, [6]).  In addition to damaging several cellular organelles, aSyn overexpression 
and aSyn oligomers have been shown to inhibit ubiquitin-proteasome system (UPS) [7,8], and 
decreased proteasomal activity in the substantia nigra has been identified in PD patients [9]. 
Moreover, aSyn can inhibit and impair chaperone-mediated autophagy [10] and 
macroautophagy (referred as autophagy hereafter) [11], thus inducing its own accumulation. In 
addition, several reports show that proteasomal inhibition induces the aggregation of aSyn in 
cells and in vivo [12-14], stressing the importance of proteolytic balance in protein aggregation 
diseases. 
Several factors can induce and enhance the aggregation process of aSyn (for review, see [4]). 
On of them is prolyl oligopeptidase (PREP), a serine protease that can increase the aggregation 
of aSyn via direct protein-protein interaction [15,16]. PREP is also colocalized with aSyn in 
substantia nigra of post mortem samples of PD patients, supporting the role of this interaction 
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in PD pathology [17]. Recently, we have shown that inhibition of PREP by a small-molecule 
inhibitor reduces aSyn protein aggregation in vitro and in vivo by modifying the interaction 
between PREP and aSyn [15,18-20]. Moreover, we have shown that PREP is a negative 
regulator of autophagy and that PREP inhibition enhances the autophagic flux via beclin1 
dependent manner [19], leading to decreased amount of high-molecular weight (HMW) aSyn 
oligomers in cells and in aSyn transgenic mouse models. 
Several studies suggest that when proteasomal processing of the proteins is impaired, autophagy 
becomes important in degradation of accumulated proteins (for review, see [21]). Moreover, 
induction of autophagy is shown attenuate the toxicity of aSyn aggregation (for review, see 
[21]). Thus, based on our previous findings, we wanted to test whether inhibition of PREP is 
protective against a proteasomal inhibitor, lactacystin, induced toxicity and protein 
accumulation in aSyn overexpressing cell culture.  
 
Materials and methods  
Chemicals 
Chemicals used were purchased form Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 
specified. Ethanol was purchased from Altia (Helsinki, Finland). Lactacystin was purchased 
from A.G. Scientific (#L-1147; San Diego, CA, USA) and dissolved in PBS in concentration 
of 2mg/ml. The PREP inhibitor, KYP-2047 (4-phenylbutanoyl-l-prolyl-2(S)-
cyanopyrrolidine), was synthesized in School of Pharmacy, University of Eastern Finland, as 
previously described [22]. KYP-2047 has been shown to be highly potent, brain and cell 
penetrating and specific for PREP [23,24]. KYP-2047 was dissolved in DMSO at a 
concentration of 100 mM for stock. 
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Cell lines 
Stable cell lines overexpressing human A53T ([A53T]aSyn) or A30P aSyn ([A30P]aSyn)  were 
generated using a lentiviral vector as described in [25]. SH-SY5Y human neuroblastoma cell 
line without aSyn overexpression (Wt cells) was purchased from ATCC (LGC Standards; 
#CRL-2266, Middlesex, UK). Cells were cultured with Dulbecco’s modified eagle medium 
(DMEM-Glutamax, #31966-021; ThermoFisher, Waltham, MA, USA) containing 15% fetal 
bovine serum (FBS, #16000-044; ThermoFisher), 1% non-essential amino acids (NEAA, 
#11140; ThermoFisher) and 50 µg/ml Gentamycin (#15750-094; ThermoFisher). With aSyn 
overexpressing cells 1 µg/ml puromycin was added to medium for selection [18].  
Induction of aSyn aggregation by lactacystin, a proteasomal inhibitor 
For Western blot (WB) and proteasomal activity experiments, the cells were seeded in a 6-well 
plate with the density 400,000 cells/well and allowed to attach overnight. Thereafter, the cells 
were incubated for 24 h on 10 µM lactacystin with 1 µM KYP-2047 or 0.001% DMSO (vehicle 
control). The concentration of KYP-2047 was chosen based on earlier studies [18,19] and on 
dose-response experiment (Fig. S1A in supplementary material). Lactacystin dose was chosen 
based on cell viability results on dose-response experiments (Fig. 1B-D). After the incubation, 
the cells were homogenized as described below. 
Proteasome activity assay 
For determining chymotrypsin-like 20S proteasomal activity, the protocol based on Suc-Leu-
Leu-Val-Tyr-AMC (#I-1395, Bachem, Bubendorf, Switzerland) substrate was used as 
described in [19]. The fluorescence was read with Victor 2 well-plate reader (PerkinElmer, 
Waltham, MA, USA) and all assays were done in triplicate. 
Cell viability assay 
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Cells were plated with the density of 50,000 cell/well in 96-well plate and the next day 
incubated for 24 h with variable concentrations of lactacystin (10 nM, 100 nM, 1 µM, 10 µM 
and 100 µM) in the presence of 1 µM KYP-2047 or DMSO vehicle (0.001% DMSO; 150 
µL/well). To assess cell viability a standard LDH release assay was performed as previously 
described [18].  
Cell fractionation and WB 
WB was used to detect aSyn, ubiquitin accumulation and autophagy markers from cellular 
fractions. The cells were fractioned to TBS soluble (soluble aSyn), Triton X-100 soluble 
(membrane-bound aSyn) and SDS soluble (containing SDS soluble and insoluble aSyn 
conformations) fractions as described in [26]. Before WB, the protein concentrations of TBS 
and Triton X-100 fractions were measured by using BCA method (Bio-Rad, Hercules, CA, 
USA), and the samples were loaded to 4-20% TGX gels (Bio-Rad) with equal protein amounts. 
The loading of SDS-fraction was based on protein amount of triton X-100 soluble fraction. 
Standard SDS-PAGE techniques were used, and the membranes were incubated +4 ºC 
overnight in 5% skim milk in 0.05% Tween20 in TBS. Following primary antibodies were used: 
mouse anti-aSyn (1:1000; #ab1903, AbCam), mouse anti-ubiquitin (1:1000; #3936S, Cell 
Signaling Technology, Danvers, MA, USA), mouse anti-SQSTM1/p62 (p62, 1:5000; 
#ab56416, AbCam), rabbit anti-microtubule associated protein light chain 3B I-II (LC3BI-II, 
1:1000; #L7843), rabbit anti-beclin1 (1:2000; #ab16998, AbCam) and rabbit anti-β-actin 
(loading control, 1:2000; #4967S, Cell Signaling Technology). After overnight incubation, the 
membranes were washed and incubated with appropriate HRP-conjugated secondary antibodies 
for 2 h in room temperature [for aSyn and SQSTM1/p62, goat anti-mouse HRP (dilution 1:2000 
in 5% milk, #31430; Thermo Fischer); for ubiquitin, LC3BI-II, beclin1, parkin and β-actin, goat 
anti-rabbit (dilution 1:2000; Product #31463, Thermo Fisher Scientific)]. The images were 
captured using the C-Digit imaging system (Licor, Lincoln, NE, USA). Three independent WB 
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experiments were performed. ImageJ was used for analysing bands, and the optical density 
(OD) value was calculated by comparing the OD value to the corresponding beta-actin OD 
value. 
Statistics 
Statistical analysis was done using GraphPad Prism 6 software (GraphPad Software, La Jolla, 
CA, USA) and SPSS 21 (cell viability; IBM Analytics, Armonk, NY, USA). 1-way analysis of 
variance (ANOVA) with Newman-Keuls post-hoc test or 2-way ANOVA with Bonferroni post-
hoc test were used. For cell viability data, 2-way ANOVA (general difference between 
treatments), and t-test (difference between treatments in different concentrations) were 
performed. Data is presented as Mean ± SEM and P<0.05 was considered as statistically 
significant. 
 
Results 
The effect of lactacystin and KYP-2047 on cell viability 
A 24 h lactacystin incubation (10 µM) decreased the 20S proteasomal activity 68% (Wt cells) 
to 75% ([A53T]aSyn and [A30P]aSyn cells) (Fig. 1A; P=0.0002; F1,6=67.78, 2-way ANOVA). 
1µM KYP-2047 had  no significant effects on proteasomal activity (Fig. S1B in supplementary 
material) and aSyn overexpression did not alter the basal proteasomal activity (Fig. 1A). 
Lactacystin induced cell death assayed by LDH test dose-dependently on both aSyn 
overexpressing cell lines (Fig. 1C-D; [A53T]aSyn, P<0.0001; [A30P]aSyn, P<0.0001, 2-way 
ANOVA) but not in Wt cells without aSyn overexpression (Fig. 1B). KYP-2047 significantly 
reduced the lactacystin toxicity on both aSyn cell lines (Fig. 1C-D; [A53T]aSyn, P=0.0121, 
F1,24=7.370; [A30P]aSyn, P<0.0114, F1,24=7.517, 2-way ANOVA), being the most significant 
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at 10 µM lactacystin dose (Fig. 1C-D; [A53T]aSyn, P=0.048; [A30P]aSyn, P=0.05, t-test), 
corresponding the reduction seen on aSyn oligomers with same lactacystin dose (Fig. 2). 
 
Figure 1A-D. The effect of 24h lactacystin (LC) incubation (10 µM) on 20S proteasomal 
activity and on cell viability of wild-type SH-SY5Y cells (Wt) and [A53T]aSyn and 
[A30P]aSyn overexpressing cells. LC significantly decreased the 20S proteasomal activity 
(A), while α-synuclein (aSyn) overexpression did not affect the basal proteasomal activity or 
sensitivity for LC. 24h incubation with LC (0.01-100 µM) had no effect on cell viability of non-
overexpressing Wt cells (B) but was significantly toxic to aSyn overexpressing cells (P < 
0.0001, 2-way ANOVA). KYP-2047 (1 µM) reduced the toxicity caused by LC on aSyn 
overexpressing cells (P = 0.0121 in [A53T]aSyn cells; P = 0.0114 in [A30P]aSyn cells; 2-way 
ANOVA). The effect was the most evident in 10 µM lactacystin dose (C-D). * P < 0.05 KYP-
2047 vs. vehicle, t-test; ** P < 0.01, vs control, Bonferroni post-hoc test, 2-way ANOVA. 
 
The effect of PREP inhibition on lactacystin-induced aSyn aggregation 
Lactacystin incubation increased the levels of aSyn dimers (37 kDA band) but did not have an 
effect on the levels of higher molecular weight aSyn forms in TBS fraction of either cell line 
(Fig. 2A), but increased the levels of Triton-X soluble oligomers in [A30P]aSyn cells by 114 
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(vehicle) and 153% (KYP-2047) (Fig. 2B; P=0.0416; F2,8=5.655, 1-way ANOVA). aSyn 
oligomers in SDS-fraction were increased in both aSyn overexpressing cell lines but significant 
increase compared to control was seen only in [A30P]aSyn cells (Fig. 2C; P=0.0194; 
F2,9=6,308, 1-way ANOVA; P<0.05 negative control (NC) vs. lactacystin+vehicle, Newman-
Keuls post-hoc test). In [A30P]aSyn cells, KYP-2047 significantly decreased the levels of 
lactacystin-induced aSyn oligomers in SDS fraction (93% reduction compared to vehicle) (Fig. 
2C; P<0.05 lactacystin+vehicle vs. lactacystin+KYP-2047, Newman-Keuls post-hoc test) and 
similar trend was seen in the SDS fraction of [A53T]aSyn cells. Lactacystin incubation did not 
result in aSyn oligomerazion in wildtype SH-SY5Y cells without aSyn overexpression and 
monomeric form of aSyn was not changed in any of the fractions (see Fig. S2 and S3 in 
supplementary material). 
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Figure 2A-F. The effect of lactacystin (LC) on α-synuclein (aSyn) and ubiquitinated 
(UbiQ) protein levels in cell culture. 24h incubation of LC (10 µM) had no effect on TBS-
soluble aSyn (A, TBS) but significantly increased the levels of TritonX-soluble (TrX) aSyn 
oligomers (membrane-bound) on [A30P]aSyn cells while simultaneous incubation with KYP-
2047 had no effect on this (B). Increase of aSyn oligomers were seen both on SDS-fraction of 
[A53T]aSyn and [A30P]aSyn cells (C, SDS) and KYP-2047 was able to counter this effect 
significantly in [A30P]aSyn cells (C). LC did not have effect on aSyn levels on non-
overexpressing SH-SY5Y wild-type cells (Fig. S2 in supplementary materials). LC incubation 
increased the UbiQ protein levels compared to control only on TBS (soluble) fraction of non-
overexpressing cells and [A53T]aSyn cells (D) but not in [A30P]aSyn cells. LC did not change 
UbiQ levels in TritonX or SDS fractions (E-F). NC, negative control. * P < 0.05, ** P < 0.01, 
Newman-Keuls post-hoc test, 1-way ANOVA. 
 
The effect of lactacystin and PREP inhibition on proteasomal and autophagy markers 
Ubiquitin levels were significantly increased after lactacystin administration in TBS soluble 
fraction of Wt (increase of 60-72%) and [A53T]aSyn cells (increase of 73%) (Fig. 2D; Wt, 
P=0.0140; F2,8 = 9.436; [A53T]aSyn, P=0.0082; F2,8=11.87; 1-way ANOVA), and KYP-2047 
had no effect on ubiquitin levels. No significant increase was seen in Triton-X or SDS fractions 
(Fig. 2E-F).  
The levels of a protein accumulation marker, p62, was increased in TBS and SDS fractions 
(Fig. 3A-C; Wt, P=0.0379; F2,8=6.792; P < 0.05 NC vs. lactacystin +vehicle and NC vs. 
lactacystin +KYP-2047, Newman-Keuls post-hoc test; [A53T]aSyn, P=0.0143; F2,8=9.369; 
TBS fraction: P<0.05 NC vs. lactacystin+vehicle and NC vs. lactacystin+KYP-2047, Newman-
Keuls post-hoc test; [A30P]aSyn, P=0.0181; F2,8=7.511; P<0.05 NC vs. lactacystin+vehicle and 
NC vs. lactacystin+KYP-2047, Newman-Keuls post-hoc test). SDS-fraction: Wt, no 
significance; [A53T]aSyn, P=0.0101; F2,8=10.50; P<0.01 NC vs. lactacystin+vehicle, 
Newman-Keuls post-hoc test; [A30P]aSyn, P=0.0011; F2,9=15.99; P<0.0001 NC vs. 
lactacystin+vehicle, P<0.001 lactacystin+vehicle vs. lactacystin+KYP-2047, Newman-Keuls 
post-hoc test, 1-way ANOVA). In TrX fraction, p62 was elevated but it did not reach 
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significance in OD analysis. Compared to vehicle, KYP-2047 reduced the lactacystin-induced 
p62 accumulation in SDS fraction of [A30P]aSyn overexpressing cells by 72% (Fig. 3C; P<0.01 
lactacystin+vehicle vs. lactacystin+KYP-2047, Newman-Keuls post-hoc test). However, in 
[A53T]aSyn cells there was no statistically significant difference between NC and 
lactacystin+KYP-2047 groups, and p62 levels were decreased by KYP-2047 73% compared to 
lactacystin+vehicle (Fig. 3C). 
Lactacystin incubation increased the levels of LC3BII, an autophagosome marker, (Fig. 3D) 
suggesting induced autophagy. KYP-2047 increased LC3BII compared to negative control in 
Wt (81%) and [A53T]aSyn (166%) cells but not significantly compared to lactacystin and 
vehicle treatment (Fig 8D; Wt cells: P=0.0172; F2,10=6.273 1-way ANOVA; P<0.05 NC vs. 
lactacystin+KYP-2047 Newman-Keuls post-hoc test; [A53T]aSyn cells: P=0.051; F2,13=3.771 
1-way ANOVA; P < 0.05 NC vs. lactacystin+KYP-2047 Newman-Keuls post-hoc test). 
Furthermore, lactacystin had no effect on beclin1 protein levels (Fig. 3E) but KYP-2047 had a 
trend to increase beclin1 protein levels (no significance in OD analysis) as seen in our previous 
study [19]. We also studied the effect of LC and KYP-2047 on parkin, an ubiquitin E3 ligase, 
which participates in protein ubiquitination and UPS targeting. We observed significantly 
decreased levels of parkin after LC treatment and KYP-2047 had no effect on parkin levels 
(Fig. 3F; Wt: P=0.0008; F2,8=29.09; P < 0.01 NC vs. lactacystin+vehicle, P<0.001 NC vs. 
lactacystin+KYP-2047, Newman-Keuls post-hoc test); [A53T]aSyn, P=0.0039; F2,8=16.13; 
P<0.01 NC vs. lactacystin+vehicle and NC vs. lactacystin+KYP-2047, Newman-Keuls post-
hoc test; [A30P]aSyn: P=0.0021; F2,8=20.43; P<0.01 NC vs. lactacystin+vehicle and NC vs. 
lactacystin+KYP-2047, Newman-Keuls post-hoc test, 1-way ANOVA). 
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Figure 3A-E. The effect of a proteasome inhibitor, lactacystin (LC), incubation on 
autophagy markers in cell culture. LC (10 µM, 24 h) incubation induced significant increase 
of a protein accumulation marker, p62, in TBS and SDS fractions (A-C). KYP-2047, a prolyl 
oligopeptidase inhibitor, significantly blocked the LC induced increase of p62 in SDS fraction 
of [A30P]aSyn cells (C). LC incubation caused an increase on the autophagosome marker, 
LC3BII (D) but it was not statistically significant in optical density (OD) analysis. In wild-type 
(Wt) and [A53T]aSyn cells, KYP-2047 had significant effect on LC3BII compared to vehicle 
treatment. LC did not alter beclin1 levels (E) while KYP-2047 had a trend to increase beclin1 
amounts. Parkin1 levels were significantly decreased by LC (F) and KYP-2047 did not have 
effect on this. * P < 0.05, ** P < 0.01, *** P < 0.001, Newman-Keuls post-hoc test, 1-way 
ANOVA. 
 
Discussion  
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In this study, we have shown that a PREP inhibitor, KYP-2047, effectively attenuates the toxic 
effects of lactacystin in mutated aSyn overexpressing cells by decreasing the levels of 
accumulated mutated aSyn. 
After aSyn and its aggregation has been identified as one of the key players in PD 
pathophysiology, also proteolytic balance has raised interest in PD research since decreased 
proteasomal activities [9] and reduced lysosomal markers (for review, see [27]) have been 
found from PD patients. UPS and chaperone-mediated autophagy are mainly responsible for 
degradation of soluble aSyn. However, misfolding and aggregation of aSyn leads to protein 
accumulation, deficits on UPS and chaperone-mediated autophagy, and thereafter to induction 
of autophagy, which can also degrade oligomeric forms of aSyn (for reviews, see [28]). 
Several studies show that activating autophagy may be beneficial to neuronal survival in aSyn 
aggregation models (for review, see [21]). We showed in our previous study that a PREP 
inhibitor, KYP-2047, enhanced autophagy via beclin1 dependent mechanism and decreased the 
amount of HMW aSyn in cell culture and in the brain of aSyn transgenic mouse [19,20]. 
Therefore, we wanted to test if PREP inhibition can overcome the aSyn aggregation induced 
by proteasomal deficit in a cellular model. Our results show that the inhibition of proteasomal 
activity in mutated aSyn overexpressing cells resulted in a dose-dependent reduction of cell 
viability and increase in aSyn oligomerization whereas cells without mutated aSyn 
overexpression were more resistant to lactacystin-induced cell death, supporting the 
significance of aSyn aggregation in lactacystin induced toxicity. Treatment of aSyn 
overexpressing cell lines with KYP-2047 significantly improved cell survival together with 
reduced HMW aSyn oligomers and SDS-insoluble p62, suggesting induced autophagy. 
Interestingly, [A30P]aSyn overexpressing cells showed accumulation also in TrX fraction and 
KYP-2047 did not have any effect on this. When considering that A30P[aSyn] is more prone 
for membrane-associated aggregation than other forms of aSyn [6], this suggests that PREP 
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inhibitors are effective towards aggregation occurring in cytosol. Although we did not see 
significant increase in LC3BII and Beclin1 in this study, these markers showed increasing trend, 
and taken together with the decrease in SDS-soluble p62, a protein accumulation marker, the 
effects of KYP-2047 seem specific for insoluble aggregated proteins, emphasizing the role for 
autophagy. Our current and previous results suggest that PREP regulates PI3K class 3 mediated 
autophagy pathway, and the exact role of PREP on this pathway needs to be studied further. 
We saw increased ubiquitin protein levels only in soluble fraction of [A53T]aSyn 
overexpressing cells. Increased ubiquitin load indicates declined proteasomal activity, and is 
also associated to Lewy bodies of PD.  However, lactacystin does not seem to induce 
accumulation of insoluble ubiquitin positive proteins. This might be explained by our 
observation of reduced parkin protein amount after lactacystin treatment. Parkin is important 
for ubiquitinylation of proteins which has been shown to be downregulated after lactacystin 
also in previous study [29]. KYP-2047 did not alter the ubiquitin levels but reduced p62 and 
aSyn oligomers in SDS-fraction suggest that PREP inhibition does not affect directly on 
degradation of soluble proteins but is more effective in inducing autophagy and clearance of 
insoluble proteins and aggregates. 
 
Conclusions 
Our results show that aSyn overexpression promotes lactacystin-induced toxicity and KYP-
2047 protects cells against cell death by decreasing insoluble mutated aSyn oligomers and p62 
levels. Several diseases with protein accumulation, including neurodegenerative diseases, 
would benefit from autophagy enhancement but there have been various problems, such as 
specificity and toxicity, in developing autophagy enhancers for clinical use [30]. However, 
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PREP inhibition may offer novel means to induce autophagy and treat synucleinopathies as 
well as other protein aggregating diseases 
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Figure S1A-B. The dose-response curve of KYP-2047 on cell viability and effect of KYP-2047 
on cell proteasomal activity. Concentrations between 10-9 to 10-5 M of KYP-2047 were tested against 
10 µM lactacystin toxicity in LDH test. Some protection by KYP-2047 was seen already at 1 nM but 
the most effective dose was 1 µM and it was chosen for experiments (A). 1 µM KYP-2047 did not 
have significant effect on cell proteasomal activity in non-overexpressing SH-SY5Y cells (B). 
 
 Figure S2.  The effect of lactacystin (LC) on α-synuclein (aSyn) levels in wild-type (Wt) non-
aSyn overexpressing cell culture. 24-h incubation of Wt cells with 10 µM LC or LC + 1 µM KYP-
2047 (LC+KYP) did not show any detectable high-molecular weight oligomers in TBS-soluble, 
TritonX-soluble (TrX) or SDS-fraction (SDS) compared to negative control (NC). Beta-actin served 
as a loading control. 
 
 Figure S3. The effect of lactacystin on monomeric form of aSyn (MaSyn). 24-h incubation of 
[A30P]aSyn or [A53T]aSyn overexpressing cells with 10 µM LC or LC + 1 µM KYP-2047 
(LC+KYP) did not show any changes on monomeric form of aSyn in TBS-soluble, TritonX-soluble 
(TrX) or SDS-fraction (SDS) compared to negative control (NC). Beta-actin served as a loading 
control. 
 
 
